Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
Northwest Biotherapeutics, Inc. (the “Company”) held an annual meeting of stockholders on February 2, 2019 (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders voted on three matters: (1) the re-elections of Ms. Linda F. Powers and Dr. Navid Malik as Class III members of the Board of Directors for 3-year terms, (2) ratification of the appointment of Marcum LLP as the Company’s auditors for 2019 and (3) approval of stock option awards to the independent members of the Board of Directors.
Votes were cast by 460,778,696 (88.7%) of the total 519,729,780 shares that were issued and outstanding on the record date of December 13, 2018, and as such were eligible to vote. The percentages in parentheses below are the percentages of the votes cast for each matter presented.
Proposal No. 1. Election of Directors.
The stockholders approved the re-elections of Ms. Linda F. Powers and Dr. Navid Malik for 3-year terms as Class III members of the Board of Directors. The votes for Ms. Powers and Dr. Malik were as follows:
| For | Withheld | Abstained | Broker Non-Votes | |
| Ms. Linda F. Powers | 306,263,568 (87.6%) | 43,387,121 (12.4%) | 111,128,007 | |
| Dr. Navid Malik | 308,628,713 (88.3%) |
41,021,976 (11.7%) |
111,128,007 |
Proposal No. 2. Ratification of Appointment of Registered Public Accounting Firm.
The stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018. The votes for reappointment of Marcum were as follows:
|
For |
Against |
Abstained |
Broker Non-Votes | |
| Ratification of Marcum LLP | 448,166,574 (97.3%) | 7,482,262 (1.6%) | 5,129,860 (1.1%) |
Proposal No. 3. Approval of Stock Option Awards to the Independent Members of the Board of Directors.
The stockholders approved the stock option awards to the independent members of the Board of Directors. The votes were as follows:
|
For |
Against |
Abstained |
Broker Non-Votes | |
| Approval of the Stock Option Awards | 303,798,949 (86.9%) | 39,782,381 (11.4%) | 6,069,359 (1.7%) |
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.
